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ABSTRACT  
Chronic kidney disease mineral bone disorder (CKD-MBD) is characterized by 
increased circulating levels of parathormone (PTH) and fibroblast growth factor-23 
(FGF23), bone disease and vascular calcification, and is associated with adverse 
outcomes. We studied the prevalence of mineral metabolism disorders, and the potential 
relationship between decreased estimated glomerular filtration rate (eGFR) and CKD-
MBD in coronary artery disease patients in a cross-sectional study of 704 outpatients 
7.5±3.0 months after an acute coronary syndrome. Mean eGFR (CKD-EPI formula) was 
75.8±19.1 ml/min/1.73 m2. Our patients showed lower calcidiol plasma levels than a 
healthy cohort from the same geographical area. In the case of men, this finding was 
present in spite of similar creatinine levels in both groups and older age of the healthy 
subjects. Most patients (75.5%) had an eGFR<90 ml/min/1.73 m2 (G2-G5 CKD stages) 
with 50% of cases showing values of 60-89 ml/min/1.73 m2 (G2). PTH (r=-0.3329, 
p<0.0001) and FGF23 (r=-0.3641, p<0.0001) inversely correlated with eGFR, while 
25OH vitamin D levels and serum phosphate levels did not. Overall, PTH levels were 
above normal in 35% of patients. This percentage increased from 19.4% in G1, to 
33.4% in G2 and 56.6% in G3-5 (p<0.001). At multivariate analysis, eGFR and 25OH 
vitamin D levels were the main independent determinants of serum PTH. Mean FGF23 
levels were 69.9 (54.5-96.3) RU/ml, and 33% of patients had FGF23>85.5 RU/mL. This 
value was 18.4% in G1, 30.0% in G2, and 59.2% in G3-5 (p<0.001). In multivariate 
analysis, eGFR was the main predictor of PTH and FGF23 levels. Increased phosphate 
levels were present in 0.7% of the whole sample, 0% in G1, 0.3% in G2 and 2.8% in 
G3-5 (p=0.011). Ninety-nine percent of cases showed calcidiol insufficiency without 
significant differences among the different degrees of eGFR. In conclusion, in patients 
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with coronary artery disease there is a large prevalence of increased FGF23 and PTH 
levels. These findings have an independent relationship with decreased eGFR, and are 
evident at eGFR 60-89 ml/min/1.73 m2. Then, mild decrements in eGFR must be taken 
in consideration by the clinician, since they are associated with progressive 
abnormalities of mineral metabolism. 
 
KEY WORDS: Glomerular filtration rate, FGF23, PTH, vitamin D, coronary artery 
disease 
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INTRODUCTION 
The KDIGO 2012 Clinical Practice Guidelines for the Evaluation and 
Management of Chronic Kidney Disease define chronic kidney disease (CKD) as the 
presence for more than 3 months of abnormalities of kidney structure or function, with 
implications for health [1]. CKD is classified based on cause, glomerular filtration rate 
(GFR) category, and albuminuria category (CGA classification). Six GFR categories are 
recognized: G1 (Normal or high, ≥90 ml/min/1.73 m2), G2 (Mildly decreased, 60-89) 
G3a (Mildly to moderately decreased, 45-59), G3b (Moderately to severely decreased, 
30-44), G4 (Severely decreased 15-29) and G5 (Kidney failure <15). CKD is defined as 
either an eGFR <60 ml/min/1.73 m2 or evidence of kidney injury such as a urinary 
albumin/creatinine ratio (UACR) >30 mg/g [1]. The basis of this classification is the 
increased relative risk of adverse outcomes associated with either a eGFR <60 
ml/min/1.73 m2 or a urinary albumin/creatinine ratio >30 mg/g [1]. These adverse 
outcomes include all-cause and cardiovascular mortality, progressive CKD and acute 
kidney injury. Interestingly, while renal outcomes are clearly associated with these two 
cut-off points (eGFR <60 ml/min/1.73 m2 or UACR >30 mg/g) an increased risk of all-
cause and cardiovascular death is already observed in patients with reduced eGFR 
(eGFR category G2, 60-89 ml/min/1.73 m2) even when UACR is below <30 mg/g [1]. 
KDIGO 2012 recommends reporting eGFR in adults using the 2009 CKD 
Epidemiology Collaboration (CKD-EPI) creatinine equation [1], since it provides an 
accurate estimate of eGFR in all GFR categories [1, 2]. In patients with heart failure, the 
CKD-EPI equations were superior to the older Modification of Diet in Renal Disease 
(MDRD) equation for predicting mortality, especially in patients with GFR >60 mL/min 
[3]. In this regard, the MDRD equation was generated from CKD patients participating 
in a clinical trial and is not accurate for patients with GFR >60 ml/min. In the past 
decade many countries followed the recommendation that, whenever serum creatinine is 
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measured, MDRD-derived eGFR is reported simply as >60 ml/min/1.73 m2 when it is 
above this value, providing only the specific result when it is <60 ml/min/1.73 m2 [4]. 
Together with the lack of routine UACR assessment, reporting eGFR as >60 
ml/min/1.73 m2 based on the MDRD equation may lead to under diagnosis of CKD by 
many non-nephrologists. This may deprive patients from early diagnosis and 
management of CKD complications, such as mineral and bone disorders (CKD-MBD). 
CKD-MBD is an early and progressive complication of CKD associated to accelerated 
vascular calcification, left ventricular hypertrophy and increased cardiovascular 
morbidity and mortality [5, 6]. The earliest manifestation of CKD-MBD is associated 
with disruption of phosphate homeostasis, vascular calcification and accelerated aging 
[7-9]. 
In this paper, the novelty point is that we have studied the status of the 
components of mineral metabolism in patients with stable coronary artery disease from 
the BACS & BAMI (Biomarkers in Acute Coronary Syndrome & Biomarkers in Acute 
Myocardial Infarction) studies [10], by assessing eGFR by the CKD-EPI equation, 
according to the most recent CKD guidelines [1]. We have divided the population in 
three groups according to GFR (<60, 60-89, and ≥90 ml/min/1.73 m2) showing that 
mild decrements in GFR have an impact on CKD-MBD parameters. This suggests that 
all patients with coronary artery disease should be screened for CKD using the CKD-
EPI equation, to detect those with an eGFR of 60-89 ml/min/1.73 m2. 
 
 
 
 
 
 
 7 
MATERIALS AND METHODS 
Study Design 
The research protocol was approved by the ethics committees of the hospitals 
and all patients signed informed consent documents. The BACS & BAMI studies 
enrolled patients admitted to four hospitals in the area of Madrid (Spain) with either 
non-ST elevation acute coronary syndrome or ST-elevation acute myocardial infarction 
[1]. Non-ST elevation acute coronary syndrome was defined as rest anginal pain lasting 
more than 20 minutes in the previous 24 hours, or new-onset class III-IV angina, along 
with transient ST depression or T wave inversion in the electrocardiogram considered 
diagnostic by the attending cardiologist and/or troponin elevation. ST-elevation 
myocardial infarction was defined as symptoms compatible with angina lasting more 
than 20 minutes and ST elevation in two adjacent leads in the electrocardiogram without 
response to nitroglycerin, and troponin elevation. Exclusion criteria were age over 85 
years, coexistence of other significant cardiac disorders except left ventricular 
hypertrophy secondary to hypertension, coexistence of any illness or toxic habits that 
could limit patient survival, impossibility to perform revascularization when indicated, 
and subjects in whom follow-up was not possible. In order to avoid variability of 
findings due to an excessive heterogeneity in the intervals between the acute event and 
blood sampling, patients not clinically stable at day six of the index event were 
excluded. 
Between July 2006 and April 2010, 1,898 patients were discharged from the 
study hospitals with a diagnosis of non-ST elevation acute coronary syndrome or ST-
elevation acute myocardial infarction. Eight hundred thirty-eight patients were enrolled 
in the study. The remaining patients were not enrolled due to age over 85 years (17.3%), 
presence of disorders or toxic habits limiting survival (29.0%), impossibility to perform 
cardiac revascularization (14.5%), coexistence of other significant cardiopathy (6.8%), 
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impossibility to perform follow-up (12.0%), clinical instability beyond day 6 of the 
index event (9.1%), refusal to participate in the study (2.0%), and impossibility of the 
investigators to enroll them (9.3%). Of 838 patients enrolled, 7 died after discharge and 
709 returned for an outpatient visit and blood sampling between January 2007 and 
February 2011 (between six and twelve months after discharge). Five patients were lost 
at follow-up leaving a total of 704 patients for analysis. 
 
Biochemical studies 
At the outpatient visit, a complete set of clinical variables were recorded and 12-
hour fasting venous blood samples were collected in EDTA, centrifuged at 2,500 g for 
10 minutes and plasma stored at -80°C in the biobank of IIS-Fundación Jiménez Díaz 
until assessment of 25 OH vitamin D (25OHD), fibroblast growth factor-23 (FGF23) 
and intact parathormone (PTH) at the laboratory of Nephrology and Mineral 
Metabolism at the Gómez-Ulla hospital. The remaining analytes were assessed at the 
Vascular Pathology and Biochemistry Laboratories at Fundación Jiménez Díaz. The 
investigators who performed the laboratory studies were blinded to clinical data. Plasma 
25OHD levels were quantified by chemiluminescent immunoassay (CLIA) on the 
LIAISON® XL analyzer (LIAISON 25OH Vitamin D total Assay DiaSorin, Saluggia, 
Italy), FGF23 was measured by an enzyme-linked immunosorbent assay which 
recognizes epitopes within the carboxyl-terminal portion of FGF23 (Human FGF23, C-
Term, Immutopics Inc, San Clemente, CA), intact PTH was analyzed by a second-
generation automated chemiluminescent method (Elecsys 2010 platform, Roche 
Diagnostics, Mannheim, Germany), phosphate was determined by an enzymatic method 
(Integra 400 analyzer, Roche Diagnostics, Mannheim, Germany). High-sensitivity C-
reactive protein (hs-CRP) was assessed by latex-enhanced immunoturbidimetry 
(ADVIA 2400 Chemistry System, Siemens, Germany). Kidney function was estimated 
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by the CKD-EPI eGFR equation [11]. 
 
Statistical Analysis 
Quantitative data that followed a normal distribution (Kolmogorov-Smirnov test) 
are presented as mean±standard deviation, and those not normally distributed are 
displayed as median (interquartile range). Qualitative variables are displayed as 
percentages. 25OHD levels were assessed as four clinically relevant categories: ≤10.0 
ng/ml (severe deficiency), 10.01-20.00 ng/ml (moderate deficiency), 20.01-30.0 ng/ml 
(insufficiency/suboptimal levels), and >30 ng/ml (sufficiency). To assess correlations, 
some values were log-transformed and Pearson´s “r” was performed. Multivariate linear 
regression models were used to identify factors independently associated with serum 
PTH or FGF23. Models were built using forward stepwise procedures in order to 
maximize r-squared with the smallest number of predictor variables. Clearly 
asymmetric variables were log transformed. Results are expressed as coeficients and 
95% confidence interval, “p” values and adjusted “r” squared value. The statistical 
significance of variables in the models was assessed by ANOVA for variables with 
normal distribution and Kruskal-Wallis tests for variables not normally distributed, 
respectively. Analyses were performed with SPSS 19.0 (SPSS Inc., New York) and 
Instat 3.10 (Graphpad Software Inc., La Jolla, CA). 
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RESULTS 
Renal function and CKD-MBD parameters were assessed in 704 outpatients 
7.5±3.0 months after a non-ST-elevation acute coronary syndrome or a ST-elevation 
acute myocardial infarction. Table 1 shows epidemiological and analytical parameters 
for the whole cohort and for 3 different KDIGO 2012 eGFR categories (G1, G2, and 
G3-5). Mean eGFR estimated by the CKD-EPI formula was 75.8±19.1 ml/min/1.73 m2. 
A majority of patients (75.5 %) had a low eGFR (GFR categories G2-G5, <90 
ml/min/1.73 m2). Indeed, over 50% of patients had an eGFR 60-89 ml/min/1.73 m2 
(G2). In the absence of albuminuria data, G2 patients are not considered as having CKD 
[1]. Compared to patients with normal eGFR (G1), patients with decreased eGFR were 
older, less frequently male and had higher hsPCR values suggesting systemic 
inflammation (Table 1). Patients with decreased eGFR also had more prevalence of 
cerebrovascular events, peripheral artery disease, atrial fibrillation and reduced ejection 
fraction. 
Only 4 patients (0.6%) were taking vitamin D supplements and none was taking 
cinacalcet or phosphate binders. Thus, the cohort can be considered to reflect natural 
history CKD-MBD parameters in coronary artery disease patients. Overall, 25OHD, 
PTH, FGF23 and serum phosphate levels differed between the three eGFR categories 
(G1, G2, and G3-5, Table 1). 
However, only PTH and FGF23 progressively changed according to 
progressively lower eGFR (Figure 1). This is in accordance to our current 
understanding of CKD-MBD. Thus, while there are CKD-associated factors (e.g. 
proteinuria with loss of protein-bound vitamin D) that may impact on 25OHD levels, 
the main risk factors for low 25OHD levels (low sun exposure and low vitamin D 
intake) are not CKD-specific [12]. In this regard, mean 25OHD levels were 19.61 ± 
8.23 ng/ml, 90% of patients in all eGFR categories had 25OHD insufficiency or 
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deficiency (<30 ng/ml, Table 1), and there was no correlation between 25OHD levels 
and eGFR (Table 2). Serum phosphate levels did not correlate with eGFR either (Table 
2). In this regard, the vast majority of patients had normal serum phosphate levels and 
only 5 (0.7%) had serum phosphate >4.5 mg/dl. This is not surprising since, given the 
toxicity of excess phosphate [13, 14], compensatory mechanisms such as increased 
serum FGF23 and PTH levels are activated very early in the course of CKD and 
hyperphosphatemia is typically not observed until eGFR categories G4 and mainly G5 
[2, 15]. Thus, the main CKD-MBD associated changes in the present coronary artery 
disease cohort were observed for PTH and FGF23.  
Median serum PTH levels were 59.7 (45.5-77.5) pg/ml and median PTH 
progressively increased as eGFR decreased as assessed by eGFR category (Table 1, 
figure 1) or as a continuous variable (r -0.3329, p<0.0001, table 2, figure 2). Overall, 
35% of study patients displayed above normal PTH levels (>74 pg/ml according to 
normal range for the lab). Among patients with normal renal function (eGFR category 
G1), 19% had high PTH levels. In eGFR category G1, low 25OHD levels are inversely 
correlated with drivers of high PTH levels (Table 2, r -0.300, p <0.0001), although 
eGFR was also a contributor (r -0.164, p 0.0326). We should remember that the original 
definition of normal 25OHD levels was based on their association with normal PTH 
levels [16]. In this regard, 25OHD levels also inversely correlate with serum PTH levels 
in all individual eGFR categories (Table 2). Furthermore, in multivariate analysis, 
eGFR and 25OHD levels were the main independent determinants of serum PTH. 
Serum phosphate (negative correlation), hsCRP (negative correlation) and FGF23 
(positive correlation) were also independently correlated with PTH (Table 3a). 
Median serum FGF23 levels were 69.9 (54.5-96.3) RU/ml, and 33% of the 
patients had FGF23 >85.5 RU/mL, considered to confer a higher risk of CKD 
progression [17]. Already in eGFR category G1, 18% of patients have FGF23 values 
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above this limit. The driver of these early changes was unclear and could be related to 
variables not assessed in the present study, such as dietary phosphate and low kidney 
Klotho levels [8, 9, 18-20]. Both within eGFR categories G2 and G3-G5 and for the 
overall cohort, a clear inverse correlation of FGF23 levels with eGFR was observed. 
Indeed, in multivariate analysis (Table 3b), eGFR was the main predictor of FGF23 
levels. Additional independent predictors were gender, phosphate, hsCRP and PTH. 
Contrary to the findings for PTH, phosphate and hsCRP were directly correlated to 
FGF23 levels. Table 4 shows the distribution of eGFR and mineral metabolism 
parameters across the different ranges of age. 
The PTH/phosphate and FGF23/phosphate ratios increased as eGFR category 
worsened (Table 1), reflecting the need of higher concentrations of phosphaturic 
hormones to maintain normal phosphate levels as glomerular phosphate filtration 
decreases and progressive resistance to their kidney effects develops[19]. 
Finally we compared our data on calcidiol plasma levels with those of a healthy 
cohort with 657 men and 1,154 women recently published in Spain by Olmos et al  [21]. 
In men, as expected, calcidiol values were lower in our study than in the healthy cohort 
(20.2±8.4 vs 23.5±7.7 ng/ml; p<0.001). This was so in the absence of significant 
differences in creatinine plasma levels (1.09±0.33 vs 1.08±0.2 mg/dl; p=0.503). Even 
more, our patients were younger than those of the healthy cohort (59.8±11.7 vs 64.6±8.4 
years; p<0.001). With regard to women, our patients also had lower calcidiol levels 
(17.9±7.3 vs 22.1±7.9 mg/dl; p<0.001). However, opposite to what we observed in men, 
age (66.4±12.7 vs 63.2±9.8 years; p<0.001) and plasma creatinine levels were higher 
than those of healthy subjects (0.94±0.36 vs 0.90±0.20 mg/dl; p=0.002)  
 
 
DISCUSSION 
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The main findings of this study are that most patients with coronary artery 
disease have a decrease in calcidiol plasma levels, which is more prevalent than in 
healthy subjects of the same geographical area. Of special interest, in the subgroup of 
men this finding was present despite both similar creatinine plasma levels in both 
populations. In addition, the age of our patients was significantly higher than that of the 
healthy cohort, meaning that the lower calcidiol levels found in men with coronary 
disease may not be attributed to a poorer renal function or to an older age. It must be 
emphasized than patients with life threatening comorbidities, among which were those 
on hemodialysis, were excluded from our study.  
Of great interest, the abnormalities in mineral metabolism were present at CKD-
MBD with eGFR<90 ml/min/1.73 m2. There is a high prevalence of reduced eGFR in 
patients with coronary artery disease. While the current data do not allow a firm 
diagnosis of CKD for patients on eGFR categories G1 and G2, due to the lack of 
confirmation in a second dataset three months apart and the lack of availability of 
UACR values (as is frequently the case for cardiology patients), we provide evidence 
that these low values of eGFR, even within eGFR category G1, may be adversely 
affecting CKD-MBD parameters such as PTH and FGF23 and, thus, may be potentially 
contributing to findings frequently observed in coronary artery disease patients such as 
left ventricular hypertrophy, vascular and valve calcification and high mortality rates 
[20,22-32]. 
CKD is present in a substantial proportion of patients with coronary artery 
disease. In pooled data from five international multicenter trials 16% of 13,307 patients 
with acute coronary syndrome had eGFR <60 mL/min/1.73 m2 [33]. More recently, the 
CLARIFY registry showed that 22.1% of patients with stable coronary artery disease 
have an eGFR below this level [34], a similar proportion to the 20.3% described in the 
present study. In addition, 76% of patients had eGFR assessed by CKD-EPI under 90 
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ml/min/1.73 m2. This cut-off point includes a much higher percentage of patients than 
the usual limit of 60 ml/min/1.73 m2 to define CKD on the basis of eGFR alone (60 
ml/min/1.73 m2). However, contrary to the common perception that mild decreases in 
eGFR (G1, G2) may be associated with treatable biochemical abnormalities, we 
describe the frequent occurrence of increased serum PTH and FGF23 levels even at 
these early stages. Indeed, PTH and FGF23 negatively correlated with eGFR in the 
whole cohort, where eGFR was the main determinant of PTH and FGF23 levels in 
multivariate analysis. Furthermore, eGFR correlated with PTH levels even in eGFR 
category G1 and with FGF23 levels from eGFR category G2, suggesting an impact of 
eGFR on CKD-MBD even at eGFR levels that are often considered “normal” for age. 
Patients with CKD gradually lose the capacity to excrete phosphate due to 
reduced nephron number, which results in a trend towards a positive phosphate balance 
[19]. Mild decrements in eGFR (eGFR category G2) are already associated with 
decreased glomerular filtration of phosphate and compensatory responses to maintain 
phosphate homeostasis, such an increased FGF23 and PTH levels [8, 19]. In this regard, 
high FGF23 levels indicate a physiological response to a state of phosphate excess that 
is due to an increase in dietary intake or a reduction in kidney excretion and may be 
associated with soft tissue phosphate deposition, even in the absence of high serum 
phosphate levels. Uremia favors vascular deposition of phosphate [35]. FGF23 protects 
from excess phosphate by decreasing kidney tubular phosphate reabsorption, thus 
promoting urinary phosphate excretion, and by inhibiting activation of 25OHD to 1,25 
(OH)2 vitamin D in kidney tubular cells [36,37]. The resulting low 1,25 (OH)2 vitamin 
D levels impair calcium and phosphate absorption in the gut, thus protecting from 
dietary phosphate excess. However, low 1,25 (OH)2 vitamin D levels promote a trend 
towards hypocalcemia and increased PTH concentration [19,38]. The high prevalence of 
nutritional and sun-induced vitamin D deficiency in the general population and in 
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coronary artery disease patients could cause a decrease in 25OHD availability for 
activation in the kidneys [39]. As a result of high FGF23 and PTH levels, serum 
phosphate levels remain within normal limits up to very advanced CKD stages [5, 15]. 
Patients with reduced GFR or CKD are at increased risk of adverse cardiac 
outcomes [15,40,41]. In patients with no CKD, bone mineral disorders have also been 
linked to the severity of coronary artery disease, as seen on coronary angiography [42], 
as well as to increased carotid intima-media thickness [43] and ventricular hypertrophy 
[44]. Serum levels of 25OHD, PTH, phosphate and FGF23 have been associated with 
prevalent and incident cardiovascular disease, suggesting a role for bioregulators of 
bone and mineral metabolism in cardiovascular health. Observational studies have 
clearly linked high FGF23 and low 25OHD levels with adverse patient outcomes 
[12,20,22-28,45-47]. Studies linking high serum PTH with adverse outcomes are more 
controversial [29-32]. Since in the present study 25OHD levels were not related to 
eGFR and high phosphate levels were very uncommon, we will only discuss FGF23 and 
PTH. 
Higher FGF23 levels are independently associated with mortality and 
cardiovascular events in coronary patients and in the community as well as with risk of 
stroke independently of renal function [17,20,22-28]. In the Heart and Soul Study, 
patients in the highest tertile of FGF23 had an 83% increase in cardiovascular events 
[22]. The increased risk conferred by higher FGF23 levels may be related to its status as 
a marker of phosphate excess, as a marker of Klotho deficiency, or to direct adverse 
effects of FGF23 promoting left ventricular hypertrophy or vascular calcification [6, 9, 
19, 20, 26]. In his regard, although serum phosphate levels were mostly within normal 
limits in our study, there is a graded independent relation between higher levels of 
serum phosphate and the risk of death and cardiovascular events in people with prior 
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myocardial infarction, most of whom had serum phosphate levels within the normal 
range [48] as well as in other non-CKD populations [13,14,49,50]. 
In our study, the multivariate analysis showed that eGFR is the main determinant 
of serum FGF23 levels. In addition, phosphate, hsCRP and PTH were directly 
correlated to FGF23 levels. These associations may be causal, according to knowledge 
gathered from experimental animal models. Thus, excess phosphate is the main 
physiological stimulus increasing FGF23 levels [19,50]. In addition, systemic 
inflammation lowers kidney Klotho [51] and decreased kidney Klotho alone may result 
in higher FGF23 levels [9]. The existence of these independent drivers of FG23 levels 
may explain the presence of high FGF23 levels in 18% of patients with eGFR≥90 
ml/min/1.73 m2. Thus either systemic inflammation or excess dietary phosphate may 
result in increased FGF23 secretion. In this regard, the multivariate model only 
explained 18% of the FGF23 variability. These data suggest an important role of 
additional factors, potentially including an excess of phosphate ingestion.  
Elevated PTH has been associated with a greater prevalence and incidence of 
cardiovascular risk factors and predicts a greater likelihood of prevalent and incident 
disease and mortality [28], even in patients with stable coronary artery disease [29]. In 
the Uppsala Longitudinal Study in Adult men (ULSAM) community-based study higher 
PTH was independently associated with a 38% greater risk of cardiovascular mortality 
[30]. However, no association between PTH and the risk of coronary heart disease was 
observed in the Health Professionals Follow-up Study in 51,529 healthy professionals 
over 40-75 years of age during 10 years follow-up [31] and a recent meta-analysis did 
not show an association between PTH and all-cause mortality in CKD [32]. In our study 
there was a high incidence of elevated PTH levels in coronary patients. In multivariate 
analysis low eGFR and low 25 OH D vitamin D levels were the main independent 
determinants of higher serum PTH. In addition, there was an independent negative 
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correlation between serum phosphate and PTH. The negative correlation between serum 
phosphate and PTH levels clearly differs from the positive correlation between serum 
phosphate and FGF23 levels. This observation is consistent with excess phosphate 
being the primary driver of FGF23 secretion, while hypocalcemia and low 25OHD 
levels are the key drivers of PTH secretion. Thus, when PTH is increased in response to 
low calcium levels or to low vitamin D levels (that also impair phosphate absorption 
from the gut) the resulting increased urinary phosphate excretion may lead to lower 
serum phosphate levels. The independent positive correlation between PTH and FGF23 
may be the result of complex interactions between both molecules. Thus, FGF23 
directly suppresses PTH secretion [52]. However, the trend towards hypocalcemia as a 
result of FGF23-mediated suppression of vitamin D activation may increase PTH levels 
[19,38]. Finally, the presence of diabetes correlated inversely with PTH levels. As 
hyperglycemia is known to suppress PTH secretion [53], it could be hypothesized that 
this feature could interfere with the development of atherosclerosis in diabetes. 
However, low serum PTH levels may have also an adverse effect over the 
cardiovascular system through different mechanisms. Low PTH decreases bone turn-
over, and may lead to adynamic bone disease [54], a well-recognized clinical entity in 
CKD which is associated not only to increased risk of bone fractures but also to 
vascular calcifications that may at least partially explain the association of this disorder 
with increased mortality rates. Moreover, diabetes, as well as ageing, has been 
associated to this disorder [54]. Then, there is no reason to hypothesize that PTH 
suppression in diabetes could modify favorably the clinical course of diabetes-related 
atherosclerotic changes. 
This study has some limitations. Urine albumin, Klotho, and calcium plasma 
levels were not measured, and renal echography was not performed. These data could 
have added important information to this paper.  
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In conclusion, patients with coronary artery disease show low plasma levels of 
calcidiol even when compared with a healthy cohort. Even more, in the subgroup of 
men these results were present without differences in creatinine plasma levels and with 
coronary patients being younger than healthy controls. In addition, in our population, 
this decrease in calcidiol and an increase in FGF23 and PTH levels are already evident 
below eGRF<90 ml/min/1.73 m2. The current standard in many countries for eGFR 
assessment is the MDRD formula and actual results are only reported if <60 
ml/min/1.73 m2. This approach results in unawareness by the treating physicians of low 
eGFR in coronary artery disease patients. We propose following recent KDIGO 2012 
guidelines for CKD and implement reporting of actual eGFR values based on the CKD-
EPI formula. Further studies are needed that explore whether reducing phosphorus 
intake and/or supplementing vitamin D will restore normal PTH and FGF23 levels in 
coronary artery disease patients with reduced eGFR and whether this intervention 
improves patient outcomes. 
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Table 1. Key patient characteristics according to eGFR category (ml/min/1.73 m2) assessed by the CKD-EPI 
formula and following the KDIGO eGFR category definition (1) 
 
 
All 
n=704 
             (100%) 
Category G1         
eGFR≥90  (n=172) 
Category G2  
eGFR 60-89 (n=389) 
(55.3%) 
Category G3 -G5 
eGFR<60 (n=143) 
(2.3%) 
P 
Age (years) 61.4 ± 12.3 51.4 ± 8.6 61.9 ± 11.1 72.1 ± 9.2 <0.001 
Male Sex (%) 75.3 83.7 77.9 58.0 <0.001 
Caucasian (%) 97.0 94.2 97.4 99.3 0.023 
Present Smoker (%) 6.5 10.5 5.1 5.6 0.055 
Diabetes (%) 24.6 23.3 22.9 30.8 0.155 
Hypertension (%) 65.1 48.3 65.8 83.2 <0.001 
Dyslipidemia (%) 59.1 58.1 58.6 61.5 0.796 
Body Mass index (Kg/m2) 28.41 (25.71-30.91) 28.5 ± 4.5 29.0 ± 4.6 28.1 ± 4.2 0.111 
Cerebrovascular events (%) 3.4 1.2 2.1 9.8 <0.001  
Peripheral artery disease (%) 3.8  2.9 2.8  7.7 0.027  
Atrial Fibrillation (%) 4.8 1.2 4.1 11.2 <0.001 
Ejection fraction <40% (%) 11.8 9.3 10.0 19.6 0.005  
LAST CORONARY EVENT 
STEMI/NSTEACS (%) 38.6/61.4  38.4/61.6 38.8/61.2 38.5/61.5 0.994 
ANALYTIC PARAMETERS 
eGFR (CKD-EPI) (ml/min/1.73m2) 75.8±19.1 98.9 ± 6.2 76.1 ± 8.2 47.3 ± 10.6 <0.001 
Glycemia 100 (91.0 - 115.0) 110.3 ± 41.7 107.7 ± 30.8 111.7 ± 44.3 0.525 
HDL cholesterol (mg/dl) 42 (36.0 – 49.0) 42.6 ± 10.4 44.3 ± 10.8 44.1 ± 11.7 0.213 
LDL cholesterol (mg/dl) 81.0 (66.0 – 96.0) 85.7 ± 28.5 82.7 ± 23.7 81.3 ± 27.0 0.335 
Triglycerides (mg/dl) 111 (82.0 – 153.0) 112.5 (82.8 – 151.3) 106 (80.0 – 149.5) 119 (86.0 – 169.5) 0.138 
HS C-reactive protein (mg/dl) 1.96 (0.83 – 4.12)  1.91 (0.88 – 3.67) 1.72 (0.78 – 3.71) 2.91 (1.20 – 6.13) <0.001 
Calcidiol (ng/dl) 19.6±8.2 18.7 ± 7.5 20.4 ± 8.6 18.6 ± 8.0 0.023 
Calcidiol range  (%)     0.055 
≤10 ng/ml 10.9 10.6 10.1 13.3  
10.01 – 20.0 ng/ml 46.4 51.2 44.0 46.9  
20.01 – 30.0 ng/ml 32.3 33.5 32.1 31.5  
>30.0 ng/ml 10.4 4.7 13.7 8.4  
PTH (pg/dl) 59.7 (45.5-77.3) 54.2 (44.1 – 65.9) 58.0 (43.9 – 75.9) 75.2 (53.5 – 99.4) <0.001 
PTH > 74 pg/ml (%) 34.9 19.4 33.7 56.6 <0.001 
FGF23 (RU/dl) 69.9 (54.6-96.2) 65.7 (48.4 – 78.9) 68.1 (53.9 – 89.1) 98.5 (72.5 – 159.0) <0.001 
FGF23 >85.5 RU/ml (%) 33.2 18.4 30.0 59.2 <0.001 
Phosphate (mg/dl) 3.21±0.54 3.25 ± 0.54 3.15 ± 0.51 3.30 ± 0.63 0.018 
Phosphate > 4.5 mg/ml (%) 0.7 0 0.3 2.8 0.011 
PTH/phosphate ratio 18.6 (13.8 – 25.2) 16.6 (12.5-21.9) 18.6 (13.7-24.6) 22.8 (16.0-32.4) <0.001 
FGF 23/phosphate ratio 22.5 (17.5 – 31.8) 19.6 (15.6-26.0) 22.1 (17.4-29.5) 32.7 (22.5-48.1) <0.001 
Calcidiol/phosphate ratio 5.88 (4.31 -7.82) 5.74 (4.3-7.2) 6.03 (4.57-8.16) 5.68 (3.53-7.65) 0.011 
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Categorical variables are presented as percentages, quantitative variables with normal distribution as meanSD and 
those not normally distributed as median (interquartile range). 
STEMI: ST-Elevation Myocardial Infarction. NSTEACS: Non-ST Elevation Acute Coronary Syndrome; eGFR: 
estimated Glomerular Filtration Rate; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; HS: High-
Sensitivity; PTH: parathormone; FGF-23: Fibroblast Growth Factor-23. 
P value refers to the comparison among G1, G2 and G3-5 groups. 
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Table 2. Univariate correlations between individual CKD-MBD parameters according to eGFR category 
assessed by the CKD-EPI formula and following the KDIGO eGFR category definition [1].  
 
 PTH Phosphate 25OH vitamin D FGF23 
G1 eGFR90 ml/min/1.73m2 
PTH  --- -0.112  
ns 
-0.300 
(p <0.0001) 
-0.034 
ns 
FGF23  -0.034 
ns 
0.1041 
ns 
-0.1583 
ns 
--- 
CKD-EPI eGFR -0.164 
(p 0.0326) 
-0.0205 
ns 
-0.015 
ns 
-0.0373 
ns 
G2 eGFR 60-89 ml/min/1.73 m2 
PTH --- -0.097 
ns 
-0.3325 
(p<0.0001) 
0.1449 
(p 0.0085) 
FGF23 0.1449 
(p 0.0085) 
0.1316 
(p 0.0171) 
-0.1243 
(p 0.0241) 
---- 
CKD-EPI eGFR -0.0833 
ns 
-0.0458 
ns 
-0.0146 
ns 
-0.1808 
(p 0.0009) 
G3-G5 eGFR<60 ml/min/1.73 m2 
PTH  --- -0.202 
ns 
-0.318 
(p 0.001) 
0.270 
(p 0.006) 
FGF23 0.270 
(p 0.006) 
0.205 
ns 
-0.024 
ns 
--- 
CKD-EPI eGFR -0.559 
(p 0.000) 
0.052 
ns 
-0.090 
ns 
-0.342 
(p 0.000) 
All 
PTH  --- -0.0918 
(p 0.0252) 
-0.3229 
(p<0.0001) 
0.2012 
(p<0.0001) 
FGF23  0.2012 
(p<0.0001) 
0.1173 
(p 0.0042) 
-0.1369 
(p 0.0008) 
--- 
CKD-EPI eGFR -0.2874 
(p<0.0001) 
-0.0154 
ns 
0.0097 
ns 
-0.3425 
(p<0.0001) 
Ns: non-significant difference 
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Table 3 
A. Multivariate analysis of predictors of PTH levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R2= 0.2747 
 
 
 
 
 
 
 r 
95 % CI  
P  Low High 
Constant 4.700 4.187 5.214 <0.0001 
Age 0.000 -0.003 -0.003 0.8997 
Sex (male) -0.084     -0.155  -0.012      0.0215 
Diabetes -0.145     -0.212   -0.077      <0.0001 
Hypertension 0.053     -0.012    0.118      0.1111 
Current Smoker -0.086     -0.202    0.029      0.1421 
Dyslipidemia -0.051     -0.109    0.007      0.0858 
Ejection fraction <40%  0.050     -0.039    0.139      0.2666 
eGFR (CKD-EPI) -0.006     -0.008   -0.004      <0.0001 
HS C-reactive protein -0.058     -0.114   -0.002      0.0419 
Calcidiol -0.014     -0.017   -0.010      <0.0001 
Phosphate -0.068     -0.122   -0.015      0.0119 
Ln FGF 23 0.084      0.031    0.137      0.0019 
Body Mass Index 0.003      -0.003   0.010      0.3460 
Cerebrovascular events -0.022     -0.165    0.121      0.7642 
Peripheral artery disease 0.031     -0.110    0.172      0.6665 
Atrial Fibrillation -0.026     -0.165    0.113      0.7117 
 32 
B. Multivariate analysis of predictors of FGF-23 levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R2= 0.178 
CI: Confidence Interval; eGFR: estimated Glomerular Filtration Rate; HS: High Sensitivity; FGF-23: Fibroblast 
Growth Factor-23. PTH: Parathormone. 
 
 
 
 
 
 
 
 r 
95 % CI  
P  Low High 
Constant 4.212 3.274 5.150 <0.0001 
Age -0.005 -0.010 -0.000 0.0407 
Sex (male) -0.191 -0.301 -0.080 0.0007 
Diabetes 0.048 -0.058 0.155 0.3739 
Hypertension 0.034 -0.067 0.135 0.5033 
Current Smoker 0.077 -0.102 0.257 0.3969 
Dyslipidemia -0.029 -0.119 0.062 0.5310 
Ejection fraction <40%  0.029 -0.109 0.167 0.6783 
eGFR (CKD-EPI) -0.009 -0.012 -0.006 <0.0001 
HS C-reactive protein 0.106 0.019 0.193 0.0165 
Calcidiol -0.002 -0.008 0.003 0.3895 
Phosphate 0.101 0.018 0.183 0.0171 
Ln PTH 0.202 0.075 0.330 0.0019 
Body Mass Index 0.002 -0.008 0.013 0.6465 
Cerebrovascular events -0.081 -0.303 0.141 0.4730 
Peripheral artery disease 0.202 -0.016 0.420 0.0694 
Atrial Fibrillation 0.199 -0.016 0.415 0.0692 
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Table 4. Estimated glomerular filtration rate and parameters of mineral 
metabolism stratified by age 
 
Categorical variables are presented as percentages, quantitative variables with normal distribution as meanSD and 
those not normally distributed as median (interquartile range). 
eGFR: estimated Glomerular Filtration Rate; FGF-23: Fibroblast Growth Factor-23¸ PTH: parathormone. 
 ≤ 60 years 
n=358 
>60-75 years 
n = 243 
 
>75 years 
 n=103 
p 
eGFR (ml/min/1.73m2) 85.1 ± 16.5 69.6 ± 16.2 58.5 ± 16.0 <0.001 
Calcidiol (ng/dl) 19.2 (14.1 - 24.5) 19.3 (13.5 - 25.6) 16.1 (12.8 - 21.3) 0.015 
FGF23 (RU/dl) 66.6 (51.7 - 85.0) 76.5 (56.8 - 103.8) 81.3 (61.1 - 124.9) <0.001 
PTH (pg/dl) 55.5 (43.0 - 69.6) 60.2 (46.9 - 80.8) 77.6 (50.8 - 97.9) <0.001 
Phosphate (mg/dl) 3.22 ± 0.57 3.17 ± 0.53 3.23 ± 0.53 0.484 
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FIGURE LEGEND 
Figure 1. CKD-MBD parameters in different estimated glomerular filtration rate 
(eGFR) categories (G1 Normal renal function, eGFR > 90 ml/min/1.73 m2, G2 Mildly 
decreased eGFR 60-89 ml/min/1.73 m2, and G3-5 < 60 ml/min/1.73 m2). A. Serum 
PTH; B. Serum FGF23; C. Serum 25 OH vitamin D; D. Serum phosphate. 
 
Figure 2. Correlation between PTH, FGF23, 25 OH vitamin D or serum phosphate and 
estimated glomerular filtration rate (eGFR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
